+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Expression of matrix metalloproteinases in primary Acute Myelogenous Leukemia cells



Expression of matrix metalloproteinases in primary Acute Myelogenous Leukemia cells



Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 70




(PDF emailed within 1 workday: $29.90)

Accession: 031386415

Download citation: RISBibTeXText


Related references

Expression of membrane-type matrix metalloproteinases in acute myelogenous leukemia. Blood 98(11 Part 1): 323a, November 16, 2001

Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: Comparison with normal bone marrow cells. British Journal of Haematology 105(2): 402-411, 1999

Extra cellular matrix proteins protect acute leukemia cells against chemotherapeutic drugs induced apoptosis Clinical significance of VLA4 expression on acute myelogenous leukemia at diagnosis. Blood 96(11 Part 1): 824a, November 16, 2000

mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leukemia Research 34(1): 32-37, 2010

Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases. Journal of Cancer Research & Clinical Oncology 123(2): 100-106, 1997

Regulation of WAF1/CIP1 protein expression in myeloid leukemia cell lines and in primary acute myelogenous leukemia cells. Blood 84(10 SUPPL 1): 376A, 1994

Expression and activation of SHC, ERK, JNK signalling proteins in primary cells of acute myelogenous leukemia. Blood 92(10 SUPPL 1 PART 1-2): 185B, Nov 15, 1998

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology 84(3): 239-251, 2010

Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23(6): 1341-1344, 1996

Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells. European Journal of Dermatology 11(5): 420-423, 2001

Matrix metalloproteinases expression in HL-60 promyelocytic leukemia cells during apoptosis. Apoptosis 5(2): 165-172, 2000

Immuno potentiation by vesicular stomatitis virus lysed acute myelogenous leukemia cells on acute myelogenous leukemia patients tested by delayed hyper sensitivity skin reactions. Scandinavian Journal of Immunology 6(10): 1188, 1977

Stimulating capacity of leukemia cells from acute non-lymphocytic leukemia, chronic myelogenous leukemia, blastic crisis of chronic myelogenous leukemia, and chronic myelomonocytic leukemia in allogenic 'one way' mixed lymphocyte tumor cell reaction. Nihon Ketsueki Gakkai Zasshi 43(5): 796-804, 1980

Stimulating capacity of leukemia cells from acute nonlymphocytic leukemia chronic myelogenous leukemia blastic crisis of chronic myelogenous leukemia and chronic myelo monocytic leukemia in allogeneic 1 way mixed lymphocyte tumor cell reaction. Acta Haematologica Japonica 43(5): 796-804, 1980

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta1. Wound Repair and Regeneration 7(6): 477-485, 2000